Tresiba Patient Assistance for Low-Income: How to Get Insulin Degludec Affordable

Why Tresiba Costs So Much and Why Assistance Matters

Insulin degludec (Tresiba) carries a wholesale acquisition cost that places it among the higher-priced basal insulins on the U.S. market. A single box of five FlexTouch pens can exceed $350 at retail pharmacies for cash-pay patients, according to pricing data tracked by the FDA's National Drug Code Directory. For patients who inject daily, annual spending can approach $4,200 before any discounts.

That price tag sits within a broader insulin affordability crisis. A 2024 analysis published in Diabetes Care estimated that roughly 1 in 4 U.S. adults with diabetes reported cost-related insulin underuse in the prior year, including skipping doses, rationing vials, or delaying refills [1]. The consequences are measurable: patients who ration basal insulin show mean A1C values 1.2 percentage points higher than adherent peers, per data from the CDC's National Diabetes Statistics Report [2]. Insulin degludec's ultra-flat pharmacokinetic profile, demonstrated in the BEGIN and SWITCH trials, provides lower hypoglycemia risk compared with insulin glargine U-100. But that clinical advantage disappears if patients cannot fill the prescription [3].

The good news: multiple assistance pathways exist. They differ by insurance status, income bracket, and state of residence. The sections below break down each option with current eligibility thresholds so you can identify the fastest route to affordable Tresiba.

Novo Nordisk Patient Assistance Program (PAP)

The most direct path for uninsured or underinsured low-income patients is Novo Nordisk's own PAP. This program supplies Tresiba at zero cost to approved applicants.

Eligibility requires that the applicant is a U.S. resident, lacks prescription drug coverage (or has coverage with a gap that leaves insulin unaffordable), and has a household income at or below 400% of the federal poverty level (FPL). For a single-person household in 2026 to 400% FPL is approximately $62,400; for a family of four, roughly $129,000 [4]. Applicants must submit proof of income (tax return, pay stubs, or a signed attestation), a valid prescription from a licensed prescriber, and a completed application form available at NovoCare.com.

Processing typically takes 2 to 4 weeks. During that window, Novo Nordisk offers an immediate-supply provision: qualifying patients can receive up to a 3-month emergency supply of Tresiba while the full application is under review [5]. Once approved, enrollees receive insulin shipped directly to their prescriber's office or a designated pharmacy, with re-enrollment required annually.

One detail prescribers sometimes overlook: the PAP covers both Tresiba FlexTouch pens and Tresiba U-200 formulations. Patients prescribed the U-200 concentration (which delivers the same dose in half the injection volume) are eligible for the same $0 cost [5].

The Novo Nordisk Copay Savings Card

Commercially insured patients who face high copays have a separate tool. The Novo Nordisk Insulin Copay Savings Card reduces out-of-pocket costs to as low as $25 for a 90-day supply of Tresiba. The card covers the difference between the patient's copay and the $25 threshold, up to a maximum annual benefit (currently $3,600 per calendar year) [5].

Eligibility is straightforward. You need commercial insurance that covers Tresiba, a valid U.S. prescription, and you cannot be enrolled in any federal or state healthcare program (Medicare, Medicaid, TRICARE, or VA benefits). The card activates at the pharmacy counter and can be downloaded or requested through NovoCare.com.

A 2022 study in JAMA Internal Medicine found that manufacturer copay cards for insulins reduced out-of-pocket spending by a median of 52% among commercially insured patients, though the authors noted that these programs do not lower the drug's list price and may delay broader price reform [6]. For the individual patient filling a Tresiba prescription today, the savings card remains one of the fastest interventions available.

Patients should verify that their specific plan formulary lists Tresiba in a covered tier before activating the card. If Tresiba sits on a non-preferred tier with a $200 copay, the savings card absorbs most of that cost. If the plan excludes Tresiba entirely, the card does not apply, and the PAP or a formulary exception request becomes the better route.

Medicare and the $35 Insulin Cap

The Inflation Reduction Act (IRA), signed into law in August 2022, imposed a $35-per-month cap on insulin out-of-pocket costs for all Medicare Part D enrollees, effective January 1, 2023 [7]. This cap applies to Tresiba and every other covered insulin product. Medicare Advantage plans with integrated Part D benefits must honor the same ceiling.

For Medicare beneficiaries who previously faced donut-hole coinsurance of 25% on Tresiba (which could mean $80 or more per fill), the IRA cap cut monthly spending to $35 regardless of the plan's formulary tier [7]. The Centers for Medicare & Medicaid Services (CMS) confirmed that the cap also eliminates cost-sharing in the catastrophic phase, where patients historically still owed 5% coinsurance [8].

One caveat: the $35 cap applies only to insulin products covered by the patient's specific Part D formulary. If a Medicare plan excludes Tresiba in favor of insulin glargine, the patient must either switch to the covered insulin, file a formulary exception, or appeal. The exception process requires the prescriber to document clinical necessity. A prior authorization letter citing the SWITCH 1 and SWITCH 2 trials (which demonstrated 40% lower nocturnal hypoglycemia with Tresiba compared with glargine U-100 in type 2 diabetes) can strengthen the case [9].

Medicaid Coverage by State

Medicaid covers insulin as a mandatory benefit under federal law, but each state's Medicaid program sets its own preferred drug list (PDL). Some states list Tresiba as a preferred basal insulin. Others require prior authorization or step therapy through NPH insulin or glargine first.

As of 2026, at least 23 state Medicaid programs include insulin degludec on their preferred formularies without step therapy, based on PDL data compiled by the Endocrine Society's insulin access resource hub [10]. In states that require step therapy, prescribers can submit a prior authorization demonstrating that the patient failed or is clinically inappropriate for the preferred agent. Documented hypoglycemia on NPH or glargine U-100 is the most common basis for approval.

Copays under Medicaid are nominal. Federal rules cap Medicaid prescription copays at $4 for preferred drugs and $8 for non-preferred drugs for most enrollees [11]. Patients at the lowest income levels (below 150% FPL) may owe $0.

For patients who are newly eligible for Medicaid under ACA expansion states, enrollment through the state marketplace or directly through the state Medicaid agency is the first step. The HealthCare.gov portal directs applicants to the correct state agency.

State Pharmaceutical Assistance Programs (SPAPs)

At least 27 states and territories operate SPAPs that supplement Medicare, Medicaid, or private coverage. These programs provide additional subsidies for prescription drugs, including insulin. Eligibility thresholds and benefit designs vary widely.

New York's EPIC program, for example, covers insulin copays for residents aged 65 and older with incomes up to $75,000 (single) or $100,000 (married) [12]. New Jersey's PAAD program offers similar benefits for residents 65 and older earning below $37,581 [12]. Several states, including Maine and Connecticut, have enacted their own insulin copay caps (typically $25 to $50 per 30-day supply) that apply to both state-regulated commercial plans and certain Medicaid managed-care plans [13].

The National Council on Aging's BenefitsCheckUp tool provides a free screening service that matches patients with SPAPs, Medicare Extra Help, and other subsidies based on income, state, and coverage type. Prescribers and diabetes educators should consider referring patients to this resource during medication reconciliation visits.

340B Program Access

The 340B Drug Pricing Program, administered by the Health Resources and Services Administration (HRSA), requires manufacturers including Novo Nordisk to sell outpatient drugs at deeply discounted prices to eligible healthcare organizations [14]. Covered entities include federally qualified health centers (FQHCs), disproportionate share hospitals, and Ryan White HIV/AIDS Program grantees.

Patients who receive care at a 340B-covered entity may access Tresiba at a significantly reduced price, often 25% to 50% below wholesale acquisition cost. The savings are passed on to uninsured and underinsured patients through the entity's sliding-fee scale [14]. Not all 340B entities stock every insulin, so patients should confirm availability with their provider's pharmacy.

A 2023 analysis in Health Affairs found that 340B hospitals provided $13.4 billion in uncompensated care in 2021, with insulin accounting for one of the top five drug categories dispensed through the program [15]. For low-income patients near an FQHC, this pathway can provide Tresiba at costs well below what the Novo Nordisk PAP or a copay card achieves for insured patients.

How to File a Formulary Exception or Prior Authorization

When insurance exists but Tresiba is excluded from the formulary or placed on a high-cost tier, a formulary exception request is the mechanism to obtain coverage. The process involves the prescriber submitting clinical documentation to the insurer explaining why Tresiba is medically necessary over the plan's preferred alternatives.

The strongest exception requests cite peer-reviewed evidence. The SWITCH 2 trial (N=721) demonstrated that insulin degludec reduced overall symptomatic hypoglycemia by 30% and nocturnal hypoglycemia by 42% compared with insulin glargine U-100 in patients with type 2 diabetes over 64 weeks of treatment [9]. The BEGIN Basal-Bolus Type 1 trial showed comparable A1C reduction between degludec and glargine, with significantly fewer nocturnal hypoglycemic episodes (rate ratio 0.75, P=0.024) [16]. These data points, combined with a documented history of hypoglycemia on the patient's current basal insulin, create a persuasive case for medical necessity.

Turnaround for standard exception reviews is 72 hours under CMS guidelines for Medicare plans and varies by state for commercial plans [17]. Expedited reviews (requested when the standard timeline could cause serious harm) must be completed within 24 hours.

"When we document recurrent nocturnal hypoglycemia on glargine with CGM data and reference the SWITCH trial results, our approval rate for degludec exceptions exceeds 80%," noted Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association [18].

Additional Cost-Cutting Strategies

Beyond formal assistance programs, several practical steps can reduce Tresiba spending.

Pharmacy price comparison. Cash prices for Tresiba vary by pharmacy, sometimes by more than $100 for the same product. Discount aggregators like GoodRx and RxSaver negotiate pricing with pharmacy networks, and some patients find prices as low as $250 per box through independent pharmacies. The FDA's guide on buying medicine safely provides consumer-facing guidance on verifying pharmacy legitimacy [19].

Dose optimization with U-200. Tresiba is available in a U-200 concentration that delivers the same dose in half the volume. Because each U-200 pen contains twice the units per milliliter, patients using higher daily doses (above 80 units) may get more injections per pen, potentially reducing the number of pens purchased per fill. The clinical equivalence of the U-100 and U-200 formulations was confirmed in a pharmacokinetic study published in Clinical Pharmacokinetics [20].

Combination therapy adjustment. For patients on Tresiba plus a GLP-1 receptor agonist, switching to Xultophy (insulin degludec/liraglutide fixed-ratio combination) may simplify the regimen and, depending on insurance tier placement, reduce total monthly drug costs. The DUAL V trial (N=557) demonstrated that Xultophy achieved A1C reductions of 1.3 percentage points from baseline while lowering insulin dose requirements by 25% compared with basal-bolus therapy [21].

Biosimilar awareness. As of early 2026, no FDA-approved biosimilar for insulin degludec has reached the U.S. market, though biosimilar development programs are underway [22]. Patients should monitor FDA biosimilar approval announcements for updates that could introduce lower-cost alternatives. The arrival of insulin glargine biosimilars (such as Semglee and Rezvoglar) has already reduced glargine costs by 40% to 65% at some pharmacies, offering a preview of the price impact biosimilar competition may deliver for degludec [22].

When to Switch vs. When to Fight for Coverage

Not every patient needs to battle for Tresiba coverage. For patients well controlled on NPH or glargine with no hypoglycemia concerns, the clinical benefit of switching to degludec may be marginal. The American Diabetes Association's Standards of Care 2026 recommend basal insulin selection based on patient-specific factors including hypoglycemia risk, cost, and adherence [23].

The clearest clinical indication for degludec over glargine is recurrent hypoglycemia, especially nocturnal episodes. A meta-analysis of seven randomized controlled trials (N=5,401) published in The Lancet Diabetes & Endocrinology found that degludec reduced confirmed nocturnal hypoglycemia by 32% compared with glargine U-100 across both type 1 and type 2 diabetes populations [24]. Patients on degludec also showed lower day-to-day fasting glucose variability (coefficient of variation 15.4% vs. 19.1%, P<0.001), which supports more predictable dose titration [24].

For patients who meet this clinical profile but face insurance barriers, the formulary exception pathway described above is worth the effort. For patients without a clear clinical need for degludec specifically, switching to a preferred and lower-cost basal insulin is the financially rational choice.